BID and chronic myelogenous leukemia, BCR-ABL1 positive: The BmooLAAO-I-induced upregulation of BID and FADDgene expression suggests that the toxin sensitizes leukemic cells to apoptosis,which is an advantage for the treatment of neoplasias, including CML [61].